Key factors drive MDS progression
Patients with myelodysplastic syndromes (MDS) face varying progression risks based on clinical factors such as low hemoglobin levels and platelet counts, according to
Meetings / Conferences
MDS
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
Triplet regimen shows promise in relapsed or refractory multiple myeloma
Elranatamab in combination with carfilzomib and dexamethasone demonstrated clinical efficacy and predictable safety signals, according to the investigators of a phase 1b MagnetisMM-20
Lymphoma
Mantle Cell Lymphoma
Secondary tumors after CAR-T cell therapy are rare, study finds
A review of patients treated with chimeric antigen receptor (CAR)-T cell therapy at a single institution revealed rare cases of second tumors, including
Myeloproliferative Neoplasms
US veterans face high symptom burden, limited access to care in MPNs
US military veterans with myeloproliferative neoplasms (MPNs) endure a substantial symptom burden and limited access to care, indicating suboptimal management, according to the
Cellular Therapy
Mantle Cell Lymphoma
FDA approves liso-cel for relapsed or refractory MCL
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s lisocabtagene maraleucel (liso-cel; Breyanzi) as a chimeric antigen receptor (CAR) T-cell
Multiple Myeloma
Belantamab Mafodotin Combination Improves PFS in Relapsed or Refractory Multiple Myeloma
A phase 3 trial has shown that the combination of belantamab mafodotin, bortezomib, and dexamethasone (BVd) had a significant benefit in terms of
Society Updates
Guillermo Garcia-Manero, MD | SOHO President 2024
The Board of Directors and the Steering committee of the Society of Hematologic Oncology are pleased to announce that Dr. Guillermo Garcia-Manero assumed the position of SOHO